This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
by Zacks Equity Research
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.
The Zacks Analyst Blog Highlights Johnson & Johnson, General Dynamics, Pioneer Natural Resources, Alibaba Group and Autodesk
by Zacks Equity Research
Johnson & Johnson, General Dynamics, Pioneer Natural Resources, Alibaba Group and Autodesk are part of the Zacks top Analyst Blog.
Looking to Bet On Perfect AAA Credit Ratings? Play These ETFs
by Sanghamitra Saha
In light of Fitch Ratings' downgrade of U.S. credit, investors might be interested in identifying companies and countries that still hold the desirable 'AAA' credit rating.
Q2 Earnings Season Scorecard and Research Reports for JNJ, Pioneer Natural & Others
by Sheraz Mian
Today's Research Daily features a real-time Q2 scorecard and updated reports on JNJ (JNJ), General Dynamics (GD), Pioneer Natural Resources (PXD) and others.
Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.
Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.
Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up
by Zacks Equity Research
Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
by Zacks Equity Research
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.
Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.
Company News for Aug 1, 2023
by Zacks Equity Research
Companies in The News Are: XOM, JNJ, ON, NFLX
Forget Soft Landing for Economy, Think About a New Takeoff
by Nalak Das
At this stage, we have narrowed our search to five stocks. These are: META, GOOGL, KO, PEP, JNJ.
These 3 Quarterly Releases Positively Shocked the Market
by Derek Lewis
There have been several notable surprises throughout the Q2 earnings season so far, including those from these three companies.
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
by Zacks Equity Research
AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.
Dorian and Oxford Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Dorian and Oxford Industries are part of the Zacks Bull and Bear of the Day article.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
Fed's July Rate Hike and Comments Match Expectations: 5 Picks
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths. These are: META, GOOGL, ISRG, JNJ, PEP.
3 Top Blue Chip Stocks to Ride the Dow Rally
by Tirthankar Chakraborty
As the Dow continues to scale upward, it's prudent to invest in stocks such as JPMorgan (JPM), Walmart (WMT) and Johnson & Johnson (JNJ) that are listed on the said index and are financially sound.
Dow Jones ETFs Continue Winning Run as Rates at 2001 High
by Sanghamitra Saha
Fed raised its benchmark interest rate by 0.25% on Wednesday, leaving room for more hikes this year. Such rising rate environment is a plus for the Dow Jones ETFs.